{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:19:20Z","timestamp":1794899960985,"version":"4.9.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Research Union Fund for High-quality health development of Guizhou Province","award":["2024GZYXKYJJXM0102"],"award-info":[{"award-number":["2024GZYXKYJJXM0102"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,8]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Spinocerebellar ataxia type 3 (SCA3), also known as Machado\u2013Joseph disease, a rare autosomal dominant neurodegenerative disorder caused by cytosine\u2013adenine\u2013guanine repeat expansions in ATXN3, lacks effective therapies. This case report highlights the clinical and genetic features of a family with 5 affected members to emphasize the challenges in diagnosis, management, and the need for targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 33-year-old male proband presented with progressive gait instability, limb incoordination, and dysarthria for more than 2 years. The symptoms worsened in cold weather and were accompanied by head swelling and muscle weakness. The patient reported a strong family history of similar neurological symptoms across the 3 generations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>Clinical evaluation revealed cerebellar ataxia, a wide-based gait, and impaired coordination. Brain MRI revealed bilateral cerebellar atrophy. Genetic testing confirmed the presence of a pathogenic ATXN3 allele with 78 cytosine\u2013adenine\u2013guanine repeats (normal range: \u226449), which is consistent with SCA3. Familial genetic analysis identified identical mutations in 4 additional relatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Supportive treatment included improvement in circulation, neuroprotective agents, and symptomatic management. No disease-modifying therapies were administered, owing to their limited availability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient\u2019s condition did not improve during hospitalization, reflecting the progressive nature of the SCA3. Similar outcomes were observed in affected family members.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Early genetic testing is critical for a definitive diagnosis, especially in familial cases. The lack of effective therapies underscores the urgency of clinical trials that target polyglutamine toxicity. Multidisciplinary care and patient education are essential for the management of this debilitating disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000043812","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T19:00:14Z","timestamp":1755198014000},"page":"e43812","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Familial spinocerebellar ataxia type 3: A case report of multi-generational presentation"],"prefix":"10.1097","volume":"104","author":[{"given":"Ji","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-9832","authenticated-orcid":false,"given":"Hao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261117","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(10)70183-6","article-title":"Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond.","volume":"9","author":"Durr","year":"2010","journal-title":"Lancet Neurol"},{"key":"R2-20261117","doi-asserted-by":"crossref","first-page":"166699","DOI":"10.1016\/j.jmb.2020.10.033","article-title":"RAN translation of the expanded CAG repeats in the SCA3 disease context.","volume":"432","author":"Jazurek-Ciesiolka","year":"2020","journal-title":"J Mol Biol"},{"key":"R3-20261117","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/acn3.51875","article-title":"Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onset.","volume":"10","author":"Jacobi","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"R4-20261117","doi-asserted-by":"crossref","first-page":"106456","DOI":"10.1016\/j.nbd.2024.106456","article-title":"Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3\/Machado-Joseph disease.","volume":"193","author":"Raposo","year":"2024","journal-title":"Neurobiol Dis"},{"key":"R5-20261117","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/biomedicines11020247","article-title":"The homogeneous Azorean Machado-Joseph disease cohort: characterization and contributions to advances in research.","volume":"11","author":"Lima","year":"2023","journal-title":"Biomedicines"},{"issue":"Pt 11","key":"R6-20261117","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1093\/brain\/awv255","article-title":"No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra.","volume":"138","author":"Sch\u00f6ls","year":"2015","journal-title":"Brain"},{"key":"R7-20261117","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ana.25297","article-title":"Structural signature of SCA3: from presymptomatic to late disease stages.","volume":"84","author":"Rezende","year":"2018","journal-title":"Ann Neurol"},{"key":"R8-20261117","doi-asserted-by":"crossref","first-page":"104635","DOI":"10.1016\/j.nbd.2019.104635","article-title":"Pathogenesis of SCA3 and implications for other polyglutamine diseases.","volume":"134","author":"McLoughlin","year":"2020","journal-title":"Neurobiol Dis"},{"key":"R9-20261117","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/mds.28819","article-title":"Gene therapy for polyglutamine spinocerebellar ataxias: advances, challenges, and perspectives.","volume":"36","author":"V\u00e1zquez-Mojena","year":"2021","journal-title":"Mov Disord"},{"key":"R10-20261117","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.3390\/ijms24087405","article-title":"Autophagy in spinocerebellar ataxia type 3: from pathogenesis to therapeutics.","volume":"24","author":"Paulino","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R11-20261117","doi-asserted-by":"crossref","first-page":"e26624","DOI":"10.1002\/hbm.26624","article-title":"Compressed cerebellar functional connectome hierarchy in spinocerebellar ataxia type 3.","volume":"45","author":"Liu","year":"2024","journal-title":"Hum Brain Mapp"},{"key":"R12-20261117","doi-asserted-by":"crossref","first-page":"619911","DOI":"10.3389\/fcell.2020.619911","article-title":"Determining the fate of neurons in SCA3: ATX3, a rising decision maker in response to DNA stresses and beyond.","volume":"8","author":"Tu","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"R13-20261117","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1523\/JNEUROSCI.1954-20.2021","article-title":"Impaired oligodendrocyte maturation is an early feature in SCA3 disease pathogenesis.","volume":"42","author":"Schuster","year":"2022","journal-title":"J Neurosci"},{"key":"R14-20261117","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/mds.29395","article-title":"Synaptic loss in spinocerebellar ataxia type 3 revealed by SV2A positron emission tomography.","volume":"38","author":"Chen","year":"2023","journal-title":"Mov Disord"},{"key":"R15-20261117","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.ymthe.2024.02.033","article-title":"ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice.","volume":"32","author":"Schuster","year":"2024","journal-title":"Mol Ther"},{"key":"R16-20261117","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuropharm.2015.08.009","article-title":"T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.","volume":"99","author":"Chou","year":"2015","journal-title":"Neuropharmacology"},{"key":"R17-20261117","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1007\/s00415-023-11848-2","article-title":"Efficacy of cerebellar transcranial magnetic stimulation in spinocerebellar ataxia type 3: a randomized, single-blinded, controlled trial.","volume":"270","author":"Shi","year":"2023","journal-title":"J Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:00:11Z","timestamp":1794898811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":17,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043812","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"2025-04-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}